David Templeton
Vermögen: - $ am 31.05.2026
Vermögen: - $ am 31.05.2026
Dr. David Templeton was previously employed as an Executive Director & Technical Director by N4 Pharma Plc, a Director-Clinical Pharmacology by Eisai Ltd. (United Kingdom), a Head-Non Clinical Development by Celltech Ltd., and a Head-Biometrics by Merck Generics Ltd.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.12.2024 | 0 ( -.--% ) | - $ | 31.05.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
| THALIA THERAPEUTICS PLC | Vorsitzender | 21.05.2019 |
Eisai Ltd. (United Kingdom)
Eisai Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Corporate Officer/Principal | 01.01.2010 |
Celltech Ltd.
Celltech Ltd. Miscellaneous Commercial ServicesCommercial Services Provides research and development on natural science and engineering | Corporate Officer/Principal | 01.01.2004 |
Merck Generics Ltd.
Merck Generics Ltd. Pharmaceuticals: MajorHealth Technology Provides therapies and drugs products | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Eisai Ltd. (United Kingdom)
Eisai Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Celltech Ltd.
Celltech Ltd. Miscellaneous Commercial ServicesCommercial Services Provides research and development on natural science and engineering | Commercial Services |
N4 Pharma Plc
N4 Pharma Plc BiotechnologyHealth Technology Provides specialist pharmaceutical services that reformulates existing drugs and vaccines to improve their performance | Health Technology |
Merck Generics Ltd.
Merck Generics Ltd. Pharmaceuticals: MajorHealth Technology Provides therapies and drugs products | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen